Histigen

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Histigen

Quick Facts: Histigen

Property Description
Active Ingredient Betahistine
Form Oral tablet, Oral solution
Pharmacological Class Antivertigo agent, Histamine analogue
General Purpose Vestibular function modulation, Relief of dizziness/vertigo
Origin Synthetic

Histigen: Identity and Pharmacological Classification

Histigen is a recognized brand of prescription-only medicine containing the active ingredient Betahistine, typically supplied as Betahistine Dihydrochloride (C8H12N2). It is formally classified by the World Health Organization (WHO) as an Antivertigo agent (ATC code N07CA01), defining its pharmacological function as counteracting balance disorders. The medicine is a synthetic compound structurally known as a Histamine analogue, which differs from traditional antihistamines in its targeted action on the body's histaminergic system. This unique identity allows it to specifically modulate nervous system activity to support the body’s mechanisms for maintaining balance.


Composition, Origin, and Available Forms

Structurally, the preparation is a single active ingredient product, combining the synthetic Betahistine molecule with pharmaceutical excipients. Histigen is differentiated in the market by its availability as both an oral solid preparation in the form of tablets and as an oral liquid preparation (solution). This dual format offers flexibility for patients requiring the oral route of administration. Research into Betahistine’s efficacy confirms its clinical recognition for vestibular function modulation, which is useful in aiding patients with chronic unsteadiness.


General Purpose for Balance and Vestibular Function

As an Antivertigo agent, the primary purpose of Histigen is the high-level support and modulation of the vestibular function within the inner ear. Its action profile is centered on facilitating the process of vestibular compensation acceleration. The drug is designed to help relieve the frequency and severity of symptoms such as severe dizziness, feelings of spinning (vertigo), and associated discomfort related to specific inner ear or vestibular disorders. Clinical assessment confirms that the medication is useful in aiding the body’s adjustment to balance disturbances and mitigating chronic symptoms of vertigo.

Regulatory References

  1. NIH/NCBI Bookshelf: Evidence Review for Betahistine

What side effects are possible with Histigen?

Possible Side Effects and Safety Information

The safety profile of Histigen (Betahistine) is officially documented by government regulatory bodies, detailing the types and frequencies of adverse reactions observed during clinical use and post-marketing surveillance. These effects are classified according to standard regulatory system-organ classes (SOCs).


Adverse Reaction Classification

The most commonly listed adverse reactions for Histigen are classified as Common, affecting up to 1 in 10 individuals. These include Nausea, Dyspepsia (indigestion), and Headache. Other effects are classified as Not Known (frequency cannot be estimated from available data), and these involve Vomiting, Abdominal Distension, Bloating, Palpitations, and Somnolence (drowsiness).

Documented effects are grouped into SOCs such as Gastrointestinal Disorders (e.g., nausea, dyspepsia, abdominal pain), Nervous System Disorders (headache, somnolence), and Immune System Disorders.


Serious Reactions and Safety Constraints

The regulatory safety profile documents serious manifestations of hypersensitivity, including Anaphylaxis and Angioneurotic Oedema.

Histigen is officially contraindicated (must not be used) in patients with Phaeochromocytoma (an adrenal gland tumour) and those with an active peptic ulcer. Official caution is specifically advised for individuals with pre-existing conditions such as Bronchial Asthma, a history of peptic ulceration, and severe hypotension.

Regarding specific populations, use in the pediatric population (under 18 years of age) is generally not recommended due to a lack of sufficient data on safety and efficacy. Gastrointestinal effects can sometimes be mitigated by taking the medicine with or after a meal, as advised in regulatory labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the manifestations and required emergency response for Histigen (Betahistine) overdose. For any suspected overdose event, it is required to seek immediate medical attention and contact a Poison Control Centre or hospital emergency department right away, as specified in government guidance.

Overdose presentations documented in official sources range from milder, general symptoms to severe systemic outcomes. Symptoms reported in association with overdose include nausea, vomiting, abdominal pain, somnolence (drowsiness), and ataxia. The ingestion of very high doses, particularly in intentional overdose or combination with other substances, is associated with the most severe outcomes.

Serious complications cited in regulatory labeling include convulsions (seizures), and serious cardiac and pulmonary complications.

Overdose Management Guidance Official Regulatory Statement
Antidote Status No specific antidote is known for Betahistine overdose.
Procedural Steps Treatment should include standard symptomatic and supportive measures, which may involve gastric lavage or activated charcoal.

Treatment is directed toward addressing the symptoms and providing supportive care, with hospital observation often necessary due to the potential for severe, life-threatening outcomes.

Therapeutic Uses of Histigen

What Histigen Treats: Main Uses and Benefits

The primary role of Histigen is to provide symptomatic relief in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed. It is commonly used when symptom manifestations become difficult to tolerate or interfere with daily stability. The medication is frequently utilized to help with symptoms related to conditions like Ménière's disease.


Easing Acute Symptom Burden

Histigen is applied within clinical settings that involve acute or disruptive symptom patterns, and periods of acute symptomatic episodes. It helps address groups of symptoms that may become intense or disruptive, such as those associated with vertigo, tinnitus, and hearing loss. This medication is often used during phases when symptoms become more noticeable and may lead to functional strain. It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations. The medication provides supportive relief that helps ease the overall symptom burden during periods of heightened symptoms.


Management of Functionally Disruptive Manifestations

This medication is relevant across conditions characterized by episodic or fluctuating symptom patterns. Histigen provides supportive relief that assists with maintaining functional stability when symptoms interfere with routine activities. It is applied when short-term symptomatic assistance is appropriate.

Quick Fact: Relief for Symptoms Related to Heightened Physiological Activity Histigen is considered relevant for easing symptoms that interfere with daily comfort and may lead to functional strain.

Eligibility and Restrictions for Use

Official Population Eligibility for Histigen

Histigen (Betahistine) is approved for use in adults aged 18 years and over, including the elderly. Its use is defined by specific regulatory exclusions and conditional warnings that govern who may or may not take the medicine.

Contraindicated Populations

Histigen is contraindicated (must not be used) in patients with the following conditions, as stated in the official regulatory documents:

  • Phaeochromocytoma: A tumour of the adrenal gland.
  • Hypersensitivity: Known allergy to the active substance (Betahistine) or any of the inactive ingredients (excipients).
  • Active Peptic Ulcer: In some regions, the medicine is also contraindicated in patients with an active or a history of a peptic ulcer.

Restricted and Conditional Use

Regulators advise that caution should be exercised and patients must be carefully monitored if they have:

  • Bronchial Asthma.
  • A history of peptic ulceration (where not formally contraindicated).
  • Severe hypotension (low blood pressure).

Age and Physiological Status

  • Pediatric Use: The medicine is not recommended for children and adolescents under the age of 18 due to insufficient data on its safety and effectiveness in this age group.
  • Pregnancy and Lactation: Use during pregnancy is generally not recommended due to a lack of adequate human data. During breastfeeding, use is not recommended as it is unknown if the medicine is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Histigen (Betahistine) documents potential interaction patterns across pharmacokinetic and pharmacodynamic domains. The drug's structure is such that no other medicinal product is formally designated as a contraindicated drug-drug combination in primary regulatory labels.

Pharmacokinetic and Exposure Interactions Co-administration with Monoamino-oxidase (MAO) inhibitors, which includes MAO subtype B inhibitors such as Selegiline, may lead to a pharmacokinetic interaction. In vitro data indicate these substances can inhibit the metabolism of Betahistine, which formally results in increased Betahistine plasma concentration (increased exposure). This interaction is a regulatory consideration due to its potential to alter systemic drug levels.

Pharmacodynamic Interactions Interaction with other agents is also noted in the pharmacodynamic domain. The official labels indicate that co-administration with Histamine H1-antagonists (Antihistamines) is expected to lead to a mutual attenuation of effect due to the opposing actions of the two substance classes on the histaminergic system.

Administration Timing Regarding interactions with food, the official labels confirm a timing rule: the Betahistine dose may be taken with or after a meal. This administration condition is allowed to help manage potential, mild gastric complaints. No specific interaction patterns or regulatory restrictions are documented for co-use with alcohol or common herbal products.

Mechanism of Action

Histigen (Betahistine) operates through a dual mechanistic approach involving modulation of the histaminergic system in both the central nervous system (CNS) and the inner ear. The mechanism exhibits two distinct interaction types with histamine receptors.


Central Modulation via H3 Receptor Antagonism

This mechanism focuses on the drug's binding as an antagonist (or inverse agonist) to the presynaptic H3 receptors in the brainstem, which are critical for regulating balance signals. By blocking this inhibitory control, the drug increases the release and turnover of histamine in the CNS. This augmented histaminergic activity promotes neuronal plasticity within the vestibular nuclei, facilitating the process of vestibular compensation—the central nervous system's adaptive mechanism for signal re-balancing.


Peripheral H1 Partial Agonism and Perfusion Mediation

The secondary mechanism involves a weak partial agonism at the H1 receptors found on the microvasculature of the inner ear's labyrinth. This interaction leads to vasodilation of local capillaries , which mediates the flow of blood, oxygen, and nutrients to the vestibular sensory structures. This perfusion mediation affects the peripheral balance organs and works in conjunction with the primary central neuro-modulatory effect.

Dosage and Administration Information

How Histigen is used

Histigen, which contains the active substance Betahistine, is an oral medication with established administration protocols. The medicine is consistently used via the oral route, often available as tablets in strengths such as 8 mg, 16 mg, and 24 mg.

Official Administration Protocol

The medicine is designed for a divided daily dose, meaning the total daily amount must be split into separate administrations throughout the day, usually two or three times. The typical daily dose range for adults is 24 mg to 48 mg, which is individually adapted to the person’s response, but the total daily intake must not exceed 48 mg.

Administration Feature Labeled Guideline
Route of Use Oral (tablet or solution)
Timing with Food Take with or after meals
Frequency Administered in divided doses (2 to 3 times per day)

Duration and Special Use Constraints

Histigen is not intended for short-term, acute use. The full benefit of the treatment may take several weeks or months to become established, and the course of administration may therefore continue for a long duration until symptoms are under control.

Regarding specific groups, the use of Histigen is not recommended for individuals under 18 years of age due to insufficient data on efficacy and safety. Guidelines also indicate that dose adjustment is generally not necessary for older adults or individuals with existing hepatic (liver) or renal (kidney) impairment. If a scheduled dose is missed, individuals are instructed to wait and take the next dose at the regular time, rather than taking two doses to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Histigen


Evidence for Use in Menière's Disease and Related Symptoms

Histigen was studied for use in research exploring how symptoms change over time related to the frequency and intensity of symptoms associated with Menière's disease, a condition characterized by fluctuating or episodic manifestations involving vertigo, tinnitus, and hearing changes. Clinical trials examined how patient-reported outcomes describing discomfort evolved in the observed populations. Some studies suggest that data show patterns related to the frequency of vertigo attacks, but findings were mixed regarding patterns related to hearing loss or constant tinnitus. The research provides context but not individual predictions about symptom changes.


Evidence for Use in Vestibular Vertigo

Research has also explored the use of Histigen for individuals experiencing general vestibular vertigo, which involves dizzy spells linked to the inner ear. These studies often applied in research contexts involving fluctuating or unstable symptoms and monitored outcomes reflecting daily functioning or activity level. Findings indicate patterns observed in the studies contribute to understanding symptom patterns related to dizziness episodes. However, the evidence quality varies across studies, and data for certain groups remain insufficient.


Long-term Studies and Follow-up

This section describes research that has monitored the effects of Histigen over extended time periods. Long-term effects are not fully established, as the follow-up durations were limited in many initial trials. The evidence highlights that patterns observed in the studies appear to continue in some patients, though the certainty remains low for the general population over periods exceeding a few years.


What is Still Uncertain About Histigen

The main evidence gaps include the reason why some patients do experience changes in their symptoms while others do not. Research has explored this individual variability, but more data is needed. The relationship between the substance and inner ear function is also studied, but the precise way Histigen was evaluated in a clinical setting needs more clarity. The evidence quality varies, and long-term effects are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Histigen (FAQ)

Q: Does Histigen treat the symptoms or the underlying condition?

Official documents classify Histigen as an Antivertigo agent that supports the body’s mechanisms for maintaining balance. Its action is described as facilitating the natural process of vestibular compensation acceleration, which is the central nervous system’s way of re-balancing signals. This modulation helps to relieve symptoms like vertigo.

Q: Is Histigen the same as a dietary supplement?

According to official classification from regulatory bodies, Histigen is a prescription-only medicine containing the active substance Betahistine. It is formally classified as an Antivertigo agent (ATC code N07CA01). This formal designation distinguishes it from non-regulated dietary supplements.

Q: Is it true that Histigen can cause dizziness or fatigue?

The official drug label does not list fatigue as a recognized side effect, although it does list Somnolence (drowsiness) with an unknown frequency. It is important to note that the approval for Histigen is for treating symptoms like dizziness and vertigo, which is a different outcome than its approved therapeutic goal.

Q: What are the warning signs of a serious side effect from Histigen?

The safety profile documents serious hypersensitivity manifestations, including Anaphylaxis and Angioneurotic Oedema. Manifestations such as rash, swelling of the face or tongue, or difficulty breathing are described as signs for which immediate medical attention is sought.

Q: Does Histigen affect sleep patterns?

The regulatory safety profile lists Somnolence (drowsiness) as an effect with an estimated frequency of 'Not Known'. No other specific effects on overall sleep patterns are detailed in the official adverse reaction lists.

Q: Is Histigen known to cause weight gain or loss?

Weight gain or loss are not listed as recognized adverse reactions in the main regulatory documents that detail the drug’s safety profile. The official information describes common gastrointestinal effects such as nausea and indigestion.

Q: Are there any known physical dependence or withdrawal effects when stopping Histigen?

Official regulatory labels do not document physical dependence or formal withdrawal effects for Histigen. Regulatory guidance suggests that individuals communicate with a healthcare provider before discontinuing any medicine.

Q: Can I drink alcohol while I am taking Histigen?

Official regulatory documents indicate that there are no specific interaction patterns or regulatory restrictions documented for co-use with alcohol. In general, it is often recommended that individuals discuss alcohol intake with their prescriber when taking any prescription medicine.

Q: Does Histigen interact with common pain relievers like acetaminophen or ibuprofen?

Official drug labels list potential interactions primarily with MAO inhibitors and Histamine H1-antagonists (antihistamines). There are no specific interactions documented between Histigen and common over-the-counter pain relievers like acetaminophen or ibuprofen.

Q: Are there any foods or drinks I should specifically avoid when using Histigen?

Official regulatory documents state that you can eat and drink normally while using Histigen. In fact, the medicine is advised to be taken with or after meals to help manage potential, mild gastric complaints like indigestion.

Q: Can Histigen be taken with multivitamins or herbal supplements?

Official regulatory labels do not document specific interactions with standard multivitamins. However, caution is advised for herbal remedies and other supplements due to insufficient data on potential interactions.

Q: How quickly should someone expect Histigen to start working?

According to official documentation, initial improvement may be observed after a couple of weeks of treatment. However, the regulatory sources indicate that the optimal patterns of effect are sometimes observed only after a few months of consistent use.

Q: What if I don't feel any noticeable effect from Histigen right away?

Official documentation notes that the full benefits may take several weeks or months to become established, and the effect is not always immediate. Official guidance emphasizes that administration should continue as directed, acknowledging that improvement is typically gradual.

Q: Is it normal for the effect of Histigen to change over time?

Research notes that the symptom patterns observed in studies are often maintained in some patients over extended time periods. However, the evidence and certainty regarding the long-term continuation of these effects remains low for the general population.

Q: How is the effectiveness of Histigen usually measured in clinical studies?

The effectiveness of Histigen in studies is usually measured by monitoring patient-reported outcomes related to discomfort. Researchers specifically track changes in the frequency and severity of vertigo attacks and associated symptoms.

Q: What is the recommended maximum duration of treatment with Histigen described in regulatory documents?

Official regulatory documents state that the course of administration may continue for a long duration until symptoms are under control. However, the prescribing information does not specify a maximum recommended treatment period.

Q: Can people with high blood pressure or heart conditions safely take Histigen?

Official caution is specifically advised for individuals with severe hypotension (low blood pressure). The regulatory labels do not list high blood pressure or general heart conditions as contraindications or specific cautions.

Q: Is there a difference in how Histigen affects people of different age groups?

Histigen is not recommended for children and adolescents under 18 due to insufficient data. However, for older adults, the official documents state that dose adjustment is generally not necessary, suggesting no significant age-related difference in effect is recognized in the adult population.

Q: How is Histigen different from other medicines prescribed for the same condition?

Regulatory information describes Histigen as an Antivertigo agent that is a Histamine analogue, which differentiates its function from traditional antihistamines. It is noted as having a dual action mechanism and is often described as being less sedating than some other vertigo medications.

Q: Does Histigen work in a similar way to [Common Alternative Drug Name]?

Histigen’s mechanism is defined by regulatory documents as involving a unique dual action on H1 and H3 receptors in the central nervous system and inner ear. This specific mode of action is typically different from the mechanisms of action used by other common vestibular suppressants.

Q: What is the shelf life of Histigen if stored properly?

The official shelf life for the tablets is typically listed as 2 years. This duration is valid when the product is stored according to the specified conditions, such as keeping it in its original package and at a temperature not exceeding 30 C.

Q: Does Histigen contain any common allergens like gluten or lactose?

Official composition documents detailing inactive ingredients (excipients) can vary by brand and region. Some formulations are specifically noted to not contain common allergens such as lactose or gluten. Inactive ingredients typically include microcrystalline cellulose, mannitol, and citric acid.

Q: Is Histigen available over the counter (OTC) in any countries?

Histigen (Betahistine) is designated as a prescription-only medicine by regulatory bodies in countries where it is approved. It is not generally available for purchase without a prescription.

Q: Where can I find the official prescribing information document for Histigen?

The official prescribing information is available via government regulatory sources such as the EMA website (SmPC) or FDA DailyMed. This information, including the patient leaflet, can also typically be obtained from a pharmacist where the medicine is dispensed.

Q: Have there been any recent, large-scale studies on the long-term use of Histigen?

The research section highlights that long-term effects are not fully established and follow-up durations were limited in many initial trials. Newer studies have examined treatment periods extending up to 9 months, but the overall certainty for general population use over many years remains low.

Q: What kind of research evidence is cited to support the use of Histigen?

Research evidence supporting the use of Histigen comes from clinical trials focused on Menière's disease and general vestibular vertigo. These studies often monitor the drug's effect when used as a long-term prophylactic treatment to reduce the frequency of vertigo attacks.

Q: Are there any known rare side effects listed in the manufacturer's official documents?

The safety profile lists adverse reactions classified by frequency (e.g., Common) and also effects with Not Known frequency, meaning data is insufficient to estimate how often they occur. Serious reactions like Anaphylaxis are also documented in the official regulatory documents.

How should Histigen be stored and disposed of?

How to Store and Dispose of Histigen

Official regulatory guidelines define specific conditions for storing and disposing of Histigen (Betahistine) to ensure its integrity and environmental safety.

Storage Requirements

Histigen must be stored at a temperature not exceeding 30°C and should be kept in its original package to protect it from moisture. Like all medications, it is a mandatory requirement to store the product out of the sight and reach of children.

Constraint Requirement
Temperature Limit Do not store above 30°C
Packaging Store in original container
Child Safety Keep out of sight and reach of children

Disposal Instructions

Expired or unused Histigen must not be thrown into household waste or wastewater. Disposal must be carried out according to local requirements for pharmaceutical waste, which typically involves returning the product to a pharmacist or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Histigen found in:

A-Z Index: